Tvardi Therapeutics
TVRD
151 hedge funds and large institutions have $505M invested in Tvardi Therapeutics in 2019 Q4 according to their latest regulatory filings, with 27 funds opening new positions, 48 increasing their positions, 42 reducing their positions, and 18 closing their positions.
50% more first-time investments, than exits
New positions opened: 27 | Existing positions closed: 18
14% more repeat investments, than reductions
Existing positions increased: 48 | Existing positions reduced: 42
5% more funds holding
Funds holding: 144 → 151 (+7)
0.05% more ownership
Funds ownership: 1.82% → 1.87% (+0.05%)
9% less capital invested
Capital invested by funds: $558M → $505M (-$52.8M)
13% less call options, than puts
Call options by funds: $9.22M | Put options by funds: $10.6M
33% less funds holding in top 10
Funds holding in top 10: 3 → 2 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CG
Carmignac Gestion
Paris,
France
|
+$10.4M |
| 2 |
Bank of America
Charlotte,
North Carolina
|
+$4.7M |
| 3 |
KCM
Kingdon Capital Management
New York
|
+$3.7M |
| 4 |
CCMW
Cypress Capital Management (Wyoming)
Sheridan,
Wyoming
|
+$3.59M |
| 5 |
FCM
Farallon Capital Management
San Francisco,
California
|
+$2.92M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
First Manhattan
New York
|
-$8.26M |
| 2 |
OM
Opaleye Management
Boston,
Massachusetts
|
-$8.04M |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$7.38M |
| 4 |
Adage Capital Partners
Boston,
Massachusetts
|
-$3.9M |
| 5 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
-$1.92M |
TVRD Hedge Fund Activity: Q4 2019 in Review
151 of the 5,076 institutional investors tracked by Wall St. Rank reported a position in Tvardi Therapeutics (TVRD) for Q4 2019, worth a combined $505M — down 9.5% from $558M a quarter earlier.
Buyers outnumbered sellers: 27 funds opened new TVRD positions and 18 closed out — a net gain of 9 holders — while 48 added to existing stakes and 42 trimmed.
The largest buyer was Carmignac Gestion, adding an estimated $10.4M. The largest seller was First Manhattan, cutting an estimated $8.26M.
- 151 institutional investors held Tvardi Therapeutics (TVRD) as of Q4 2019, up from 144 in Q3 2019.
- Funds reported $505M of Tvardi Therapeutics stock for Q4 2019, down 9.5% quarter-over-quarter.
- 27 funds opened new Tvardi Therapeutics positions in Q4 2019 and 18 closed out, a net change of +9 holders.
- The largest Tvardi Therapeutics buyer in Q4 2019 was Carmignac Gestion, an estimated $10.4M added.
- The largest Tvardi Therapeutics seller in Q4 2019 was First Manhattan, an estimated $8.26M sold.
Based on aggregated 13F filings for Q4 2019.